Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) EBITDA: 2020-2025

Historic EBITDA for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $620,000.

  • Xeris Biopharma Holdings' EBITDA rose 103.94% to $620,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 75.19%. This contributed to the annual value of -$54.8 million for FY2024, which is 11.92% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its EBITDA stood at $620,000 for Q3 2025, which was up 132.17% from -$1.9 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year EBITDA high stood at $620,000 for Q3 2025, and its period low was -$50.8 million during Q4 2021.
  • Moreover, its 3-year median value for EBITDA was -$13.4 million (2023), whereas its average is -$11.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 131.87% in 2021, then spiked by 103.94% in 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' EBITDA (Quarterly) stood at -$50.8 million in 2021, then surged by 74.57% to -$12.9 million in 2022, then decreased by 3.48% to -$13.4 million in 2023, then spiked by 61.68% to -$5.1 million in 2024, then skyrocketed by 103.94% to $620,000 in 2025.
  • Its EBITDA stands at $620,000 for Q3 2025, versus -$1.9 million for Q2 2025 and -$9.2 million for Q1 2025.